Oligonucleotide aptamer specifically binding to EGFR (epidermal growth factor receptor) protein and application of oligonucleotide aptamer

By developing oligonucleotide aptamers that specifically bind to the intracellular domain of the EGFR protein, the off-target effects and drug resistance of EGFR-targeted drugs have been resolved, enabling highly efficient targeted therapy and diagnosis of EGFR and enhancing the efficacy of chemotherapy and immunotherapy.

CN122012512APending Publication Date: 2026-05-12ACADEMY OF MILITARY MEDICAL SCIENCES
0 Cites 0 Cited by

Patent Information

Application Number
CN202610225998.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-02-26
Publication Date
2026-05-12

AI Technical Summary

Technical Problem

Existing EGFR-targeting drugs suffer from off-target effects and EGFR target mutations in tumor cells. Traditional treatments are prone to drug resistance, and the stability of aptamer binding and spatial structural characteristics need to be improved.

Method used

Develop oligonucleotide aptamers that specifically bind to the intracellular segment of the EGFR protein, including EG2, EG3 and their variants, modify them with biotin, and use them to prepare targeted drugs and diagnostic reagents, thereby influencing signaling pathway activation and drug delivery through specific recognition of the EGFR protein.

Benefits of technology

It achieves high affinity binding to EGFR protein, inhibits tumor signaling pathways, enhances chemotherapy efficacy, reduces toxic side effects, and improves the accuracy of tumor diagnosis and the effectiveness of immunotherapy.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention provides an oligonucleotide aptamer specifically binding to EGFR protein and application, and belongs to the technical field of biological medicine. The invention provides a group of oligonucleotide aptamer sequences capable of specifically recognizing an EGFR protein intracellular fragment, the oligonucleotide aptamer sequences comprise EG2 and EG3 oligonucleotide aptamer sequences and modified sequences thereof, and the oligonucleotide aptamers can specifically recognize the EGFR protein intracellular fragment, especially can be combined with recombinant protein consisting of 668th to 1210th amino acids of the EGFR protein without being combined with other irrelevant proteins, so that the EGFR protein intracellular fragment can be specifically recognized. The polypeptide has a potential target spot closing effect, can be applied to the field of new drug research and development based on the EGFR pathway activation principle, and can be applied to research and development of related drugs targeting EGFR.
Need to check novelty before this filing date? Find Prior Art